Trial reportBMC nephrology2024
PIVKA-II but not dp-ucMGP is associated with aortic calcification in chronic kidney disease.
Trial report in BMC nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04114695 (Aortic Calcification and Central Blood Pressure in Patients With Chronic Kidney Disease), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Aortic Calcification and Central Blood Pressure in Patients With Chronic Kidney Disease
Who cites it
3 citing papers in PubMed.
- Vitamin K status and vascular calcification biomarkers as determinants of carotid plaque in peritoneal dialysis: a prospective study.Renal failure · 2026Article
- Protein Induced by Vitamin K Absence or Antagonist II in Primary Liver Cancer: Basic Research Insights and Clinical Applications.Journal of clinical and translational hepatology · 2025Review
- Vascular Calcification in Chronic Kidney Disease and Hemodialysis: Pathophysiological Mechanisms and Emerging Biomarkers.Medicina (Kaunas, Lithuania) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with chronic kidney disease (CKD) are susceptible to vascular calcification and vitamin K deficiency. Matrix gla protein (MGP) is a potent inhibitor of calcification requiring vitamin K for activation. Inactive MGP, i.e. dephosphorylated uncarboxylated MGP (dp-ucMGP), is frequently elevated in CKD along with protein induced by vitamin K absence (PIVKA-II). We investigated whether dp-ucMGP and PIVKA-II are useful markers of aortic calcification in CKD.
methodsPatients with normal or reduced kidney function underwent a non-contrast computed tomography scan of the entire aorta with subsequent blinded standard calcification scoring of the aortic wall ad modum Agatston. Blood samples were analyzed for plasma concentrations of dp-ucMGP and PIVKA-II.
results141 patients (104 with CKD stage 3-5) were included. In patients with/without CKD median (interquartile range) were dp-ucMGP 543 (503-744)/1078 (835-1682) pmol/l (P < 0.01); PIVKA-II 19.3 (16.3-23.5)/21.8 (17.2-36.8) ng/ml (P = 0.33) and aortic Agatston scores 1644 (729-4138)/7172 (2834-15360) (P < 0.01). Agatston score was positively associated with PIVKA-II (β = 0.71, P = 0.014, r
conclusionVitamin K deficiency, as estimated through PIVKA-II, but not dp-ucMGP, is weakly associated with aortic Agatston score. Yet, as markers of aortic calcification, both were outperformed substantially by age, and neither surpassed smoking nor eGFR. CLINICALTRIALS: GOV IDENTIFIER: NCT04114695.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.